Abstract
Abstract Background: Insulin-like growth factor-1 (IGF1) is a potent mitogen, whereas IGF-binding protein-3 (IGFBP3) binds and inhibits IGF1. High circulating IGF1 and low IGFBP3 are associated with increased risk of several cancers. Here we examined relations of those serum levels with the risk of hepatoma in a prospective case-control study nested in the JACC Study. Methods: A baseline survey was conducted from 1988 to 1990 and 39,242 subjects donated blood samples. Those who had been diagnosed as hepatoma were regarded as cases for nested case-control studies. Ninety-one cases and 263 controls are eligible for the present analysis. A conditional logistic model was used to estimate odds ratios (OR) for incidence of hepatoma associated with serum IGF1 and IGFBP3 levels. Results: Both IGF1 and molar ratio of IGF1/IGFBP3 were not correlated with the risk of hepatoma. After adjustment for hepatitis-viral infection, body mass index, smoking, and alcohol intake, higher molar difference of (IGFBP3 - IGF1) was associated with decreased risk of hepatoma (p for trend < 0.001), and peoples in the highest quintile had a lower risk (OR = 0.098; 95%CI = 0.026-0.368). In subgroup analyses, both in male and female, high molar difference of (IGFBP3 - IGF1) was associated with decreased risk of hepatoma (p for trend < 0.001). Both in the elderly and non-elderly, it was correlated inversely with risk of hepatoma (p for trend = 0.001, < 0.001, respectively). Conclusions: Molar difference of (IGFBP3 - IGF1) might associate inversely with the incidence of hepatoma. Citation Format: Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Yasutaka Matsunaga, Noriyuki Akutsu, Shigeru Sasaki, Takao Endo, Youichi Kurozawa, Kenji Wakai, Akiko Tamakoshi. Free IGFBP3 and the risk of liver cancer in a nested case-control study. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4306.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
